Brodszki, Nicholas
Frazer-Abel, Ashley
Grumach, Anete S.
Kirschfink, Michael
Litzman, Jiri
Perez, Elena
Seppänen, Mikko R. J.
Sullivan, Kathleen E.
Jolles, Stephen http://orcid.org/0000-0002-7394-6804
Funding for this research was provided by:
ESID (Unrestricted Educational Grant)
Article History
Received: 5 June 2019
Accepted: 20 January 2020
First Online: 17 February 2020
Compliance with Ethical Standards
:
: Dr. N. Brodszki has acted on advisory boards and as a speaker or participated in projects with CSL Behring, Baxter/Baxalta, Shire, Octapharma and Meda. Dr. A.S. Grumach has taken part in educative programs and consulting for Shire/Takeda and CSL Behring. Dr. A.S. Grumach has received a grant of researcher initiative from Shire/Takeda (IST-BRA-000778). Dr. E. Perez has acted as a consultant and speaker for Shire/Takeda, CSL Behring and Genentech. Recently, Dr. E. Perez has acted as a principal investigator/co-principal investigator for Green Cross, Therapure, Aimmune, Kedrion, CSL Behring and Prometic. Dr. K. Sullivan receives funds from the Immune Deficiency Foundation as a consultant, UpToDate as an editor and Elsevier as royalties. Prof S. Jolles has received support from CSL Behring, Takeda, Shire, Octapharma, Pharming, Biotest, SOBI, LFB, Grifols, BPL, Sanofi, GSK, UCB Pharma, The Binding Site, Weatherden and Zarodex for projects, meetings, advisory boards and clinical trials. Prof. M. Kirschfink has acted as consultant and speaker for Alexion, Novartis, Roche, Biotest, Ionis and Eurodiagnostica. Dr. A. Frazer-Abel, Dr. J. Litzman and Dr. M.R.J. Seppänen report no conflicts of interest. Administrative support for the writing group from Meridian HealthComms Ltd. with an unrestricted educational grant from ESID.